EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Reduced Metformin Concentrations in Obese Women With Human Immunodeficiency Virus Treated With Dolutegravir

Roland van Rensburg iD, Tracy Kellermann iD, Veshni Pillay-Fuentes Lorente iD, Christiena du Plessis, Catherine Orrell iD, Innocent Maposa, Chantel Schreuder iD, Lauren Jennings iD, Gert van Zyl iD, Giovanni Schifitto, Eric Decloedt iD

The Journal of Infectious Diseases · 20.12.2025 · 232 (6) · e1012-e1021

DOI: 10.1093/infdis/jiaf305 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 05.06.2025. Verfasst von Roland van Rensburg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University, Cape Town, South Africa. Hauptthemen laut MEDLINE: Metformin, Obesity, HIV Infections, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FIC NIH HHS, NIH HHS, South African Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity among women with human immunodeficiency virus (WWH) is nearly 2-fold higher than in men. Obesity is closely associated with dysglycemia, and frequently necessitates the coadministration of dolutegravir and metformin. A pharmacokinetic study in 15 nonobese healthy volunteers determined that dolutegravir increased metformin plasma exposure by 79%, prompting regulatory and guideline recommendations to limit metformin to 1000 mg/day when coadministered with dolutegravir. Obesity has been linked to lower metformin exposures, and our study aimed to verify the metformin pharmacokinetic exposure in the increasing population of obese WWH.

Methods

We conducted intensive plasma sampling in virally suppressed WWH receiving metformin extended-release 1000 mg once daily with concomitant dolutegravir 50 mg once daily. Dual-energy X-ray absorptiometry was performed to quantify body fat composition. Noncompartmental analysis of metformin and dolutegravir concentrations was performed, and our findings were compared to the reference study.

Results

We enrolled 15 participants with a mean body mass index of 45.6 kg/m2. Metformin area under the concentration-time curve over the 24-hour dosing interval (AUC0–24) was 40.9% lower and dolutegravir AUC0–24 was 54.4% lower in obese WWH compared to the reference study. Metformin and dolutegravir clearance were 1.7- and 2.2-fold higher, respectively. Linear regression did not show associations between body fat composition and metformin or dolutegravir exposures.

Conclusions

Limiting metformin to 1000 mg daily is likely to lead to underdosing in obese WWH on dolutegravir. Lower metformin exposure appears to be due to the reduced inhibitory effect of lower dolutegravir concentrations on metformin clearance and increased volume of distribution due to obesity. Our data support the revision of the current maximum dose restriction of metformin in the target population of obese WWH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminObesityHIV InfectionsHypoglycemic AgentsDolutegravirHIV Integrase InhibitorsHIVHumansFemaleAdultMiddle AgedBody Mass IndexAbsorptiometry, Photon

Stichwörter der Autor:innen

dolutegravirdrug interactionmetforminobesityunderdosing

Substanzen

MetforminHypoglycemic AgentsDolutegravirHIV Integrase Inhibitors

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University, Cape Town, South Africa.
  • Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Cape Town, South Africa.
  • Division of Medical Virology, Department of Pathology, Stellenbosch University, Cape Town, South Africa.
  • Department of Neurology, University of Rochester, Rochester, New York, USA.

ORCID-Profile: Roland van Rensburg, Tracy Kellermann, Veshni Pillay-Fuentes Lorente, Catherine Orrell, Chantel Schreuder, Lauren Jennings, Gert van Zyl, Eric Decloedt

Förderung

  • FIC NIH HHS
  • NIH HHS
  • South African Medical Research Council
  • Division of Research Capacity Development
  • Clinician Researcher Development Programme
  • South African National Department of Health
  • Discovery Foundation
  • Harry Crossley Foundation

Zitieren

APA

van Rensburg, R., Kellermann, T., Pillay-Fuentes Lorente, V., du Plessis, C., Orrell, C., Maposa, I., Schreuder, C., Jennings, L., van Zyl, G., Schifitto, G., & Decloedt, E. (2025). Reduced Metformin Concentrations in Obese Women With Human Immunodeficiency Virus Treated With Dolutegravir. The Journal of Infectious Diseases, 232(6), e1012-e1021. https://doi.org/10.1093/infdis/jiaf305

Vancouver

van Rensburg R, Kellermann T, Pillay-Fuentes Lorente V, du Plessis C, Orrell C, Maposa I, et al. Reduced Metformin Concentrations in Obese Women With Human Immunodeficiency Virus Treated With Dolutegravir. The Journal of Infectious Diseases. 2025;232(6):e1012-e1021. doi:10.1093/infdis/jiaf305

BibTeX
@article{vanRensburg2025,
  author = {van Rensburg, Roland and Kellermann, Tracy and Pillay-Fuentes Lorente, Veshni and du Plessis, Christiena and Orrell, Catherine and Maposa, Innocent and Schreuder, Chantel and Jennings, Lauren and van Zyl, Gert and Schifitto, Giovanni and Decloedt, Eric},
  title = {Reduced Metformin Concentrations in Obese Women With Human Immunodeficiency Virus Treated With Dolutegravir},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  volume = {232},
  number = {6},
  pages = {e1012--e1021},
  doi = {10.1093/infdis/jiaf305}
}
Kostenlos starten →